BNTCBenitec Biopharma Inc.
$8.74-37% 1Y
$8.74
$8.7452 weeks$16.52
Latest close: a new 52-week lowOct 8, 2026what changed →
BNTC in its own filings
BNTC's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
148
Events found in the filings · across 331 filings · the record starts in 2020
- Hard flags
- 2
Hard flags
- Most recent filing
- Oct 5, 2026
Most recent filing · Form 8-K
- Record starts
- Jun 5, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Dec 14, 2026
- Restatement admitted (non-reliance)past_3y
- 2025-09-12
- Change in certifying accountant5 occurrences
- 2026-09-30
- Delisting notice / listing-rule failure3 occurrences
- 2023-08-10
- SEC comment-letter activity31 occurrences
- 2026-04-03
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study.Regulation FD disclosure · press release
- Sep 30, 2026New Independent Registered Public Accounting Firm As previously disclosed on a Current Report on Form 8-K with the Securities and Exchange Commission that Benitec Biopharma Inc. (the “Company”) filed on September 24, 2026, the Company reported the approval of the engagement of Ernst & Young LLP (“EY”) as the Company’s …Auditor change · Form 8-K
- Sep 24, 2026Baker Tilly US, LLP (“Baker Tilly”), the Company’s independent registered public accounting firm, has served as the Company’s auditor since 2020.Auditor change · Form 8-K
- Sep 14, 2026Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update.Earnings release · press release
- May 29, 2026Election of Director On May 22, 2026, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed David Friedman to serve as a director of the Board, effective as of such date.Director or officer change · Form 8-K
- May 14, 2026Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update.Earnings release · press release
- Feb 12, 2026Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update.Earnings release · press release
- Nov 14, 2025Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update.Earnings release · press release
- Nov 7, 2025Underwritten Offering On November 5, 2025, Benitec Biopharma Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Leerink Partners LLC (“Leerink Partners”), TD Securities (USA) LLC (“TD Securities”) and Evercore Group L.L.C. (“Evercore ISI”), as …Material agreement entered · Form 8-K
- Nov 3, 2025On November 2, 2025, the Board of Directors (the “Board”) of Benitec Biopharma Inc. (the “Company”) appointed Dr. Sharon Mates to serve as a director of the Board, effective as of November 3, 2025.Director or officer change · Form 8-K
- Sep 22, 2025Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…